{"id":"control-pneumococcal-polysaccharide-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The pneumococcal polysaccharide vaccine contains inactivated pneumococcal bacteria, which are used to stimulate the body's immune system to produce antibodies against these bacteria. These antibodies help to protect against infections caused by pneumococcal bacteria.","oneSentence":"This vaccine works by stimulating the body's immune system to produce antibodies against pneumococcal bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:37.080Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of pneumococcal disease in adults 18 years of age and older"}]},"trialDetails":[{"nctId":"NCT07300267","phase":"PHASE1","title":"A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-13","conditions":"Pneumococcal Infection","enrollment":210},{"nctId":"NCT04460313","phase":"NA","title":"Nasopharyngeal Carriage of S. Pneumoniae","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2001-09-11","conditions":"Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain","enrollment":25760},{"nctId":"NCT07425392","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-02-09","conditions":"Pneumococcal Vaccines","enrollment":720},{"nctId":"NCT06077656","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Inventprise Inc.","startDate":"2023-10-25","conditions":"Pneumococcal Vaccines","enrollment":220},{"nctId":"NCT07284654","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2025-12-01","conditions":"Pneumococcal Vaccines","enrollment":4000},{"nctId":"NCT07365826","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-01-12","conditions":"Pneumococcal Vaccines","enrollment":1300},{"nctId":"NCT07252791","phase":"PHASE4","title":"Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-16","conditions":"Autoimmune Rheumatologic Disease","enrollment":114},{"nctId":"NCT05696080","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-13","conditions":"Pneumococcal Infection","enrollment":518},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT06975878","phase":"PHASE3","title":"Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-05-22","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":1092},{"nctId":"NCT05569954","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-11-07","conditions":"Pneumococcal Disease","enrollment":1484},{"nctId":"NCT07017777","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-11-14","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":600},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT07428759","phase":"PHASE1","title":"Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-10","conditions":"Pneumonia, Bacterial","enrollment":120},{"nctId":"NCT06736041","phase":"PHASE3","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-18","conditions":"Pneumococcal Immunization","enrollment":1714},{"nctId":"NCT07418372","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2026-03-12","conditions":"Tetanus, Diphtheria and Acellular Pertussis Vaccination, Tetanus, Diphtheria","enrollment":660},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT07406334","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Toddlers 12 to 15 Months of Age Receiving a Single Booster Dose","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-05-15","conditions":"Pneumonia, Bacterial","enrollment":45},{"nctId":"NCT07406347","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Reactogenicity of an Investigational Pneumococcal Vaccine in Infants Receiving 3-dose Primary Dosing Series Followed by a Booster Dose at 12 to 15 Months of Age","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-07-10","conditions":"Pneumonia, Bacterial","enrollment":60},{"nctId":"NCT05393037","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-13","conditions":"Pneumococcal Disease","enrollment":313},{"nctId":"NCT07160244","phase":"PHASE3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-25","conditions":"Healthy","enrollment":6000},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT06183216","phase":"PHASE1","title":"A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2024-01-04","conditions":"Pneumococcal Infectious Disease","enrollment":140},{"nctId":"NCT07247188","phase":"PHASE3","title":"Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT06550830","phase":"PHASE1","title":"Clinical Trial of PCV24 in Children Aged 2-17 Years","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-09-07","conditions":"Pneumococcal Infectious Disease","enrollment":119},{"nctId":"NCT06800261","phase":"PHASE1","title":"Clinical Trial of PCV24 in Infants Aged 2-23 Months","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-05-08","conditions":"Pneumococcal Infectious Disease","enrollment":180},{"nctId":"NCT05092386","phase":"PHASE1","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-01-03","conditions":"Pneumococcal Infections","enrollment":310},{"nctId":"NCT05452941","phase":"","title":"A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-10-27","conditions":"Pneumonia","enrollment":12500},{"nctId":"NCT06720038","phase":"PHASE2","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2024-11-25","conditions":"Pneumococcal Vaccines","enrollment":905},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT07333352","phase":"PHASE2","title":"PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months","status":"RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2025-09-11","conditions":"Pneumococcal Infectious Disease","enrollment":480},{"nctId":"NCT05815264","phase":"PHASE1","title":"Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and Above","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2020-09-07","conditions":"Pneumonia","enrollment":144},{"nctId":"NCT07105722","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-12","conditions":"Pneumonia, Bacterial","enrollment":127},{"nctId":"NCT07300644","phase":"PHASE2","title":"Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-11-25","conditions":"Pneumococcal Infectious Disease","enrollment":420},{"nctId":"NCT06817421","phase":"PHASE4","title":"Opportunistic Pneumococcal Immunisation Trial in MALnutrition","status":"NOT_YET_RECRUITING","sponsor":"Nick Fancourt","startDate":"2026-01","conditions":"Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines","enrollment":214},{"nctId":"NCT06678620","phase":"PHASE2","title":"Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-20","conditions":"Pneumococcal Infectious Disease","enrollment":992},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT05526716","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-09-23","conditions":"Pneumonia, Pneumococcal","enrollment":1080},{"nctId":"NCT06838000","phase":"PHASE3","title":"Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-02-28","conditions":"Pneumococcal Infections","enrollment":1268},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT05844423","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants","status":"COMPLETED","sponsor":"Vaxcyte, Inc.","startDate":"2023-03-29","conditions":"Pneumococcal Vaccines","enrollment":802},{"nctId":"NCT06790290","phase":"PHASE2","title":"Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventprise Inc.","startDate":"2025-01-27","conditions":"Pneumococcal Disease, Invasive","enrollment":421},{"nctId":"NCT03376477","phase":"PHASE2","title":"Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-09-23","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT06151288","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults","status":"COMPLETED","sponsor":"Vaxcyte, Inc.","startDate":"2023-11-08","conditions":"Pneumococcal Vaccines","enrollment":1015},{"nctId":"NCT06185842","phase":"NA","title":"The Effectiveness of a Lung Health Promotion Program Based on the 5A Self Management Support Model.","status":"COMPLETED","sponsor":"Selcuk University","startDate":"2023-11-21","conditions":"Pulmonary Disease","enrollment":49},{"nctId":"NCT05158140","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-12","conditions":"Pneumococcal Infection","enrollment":850},{"nctId":"NCT06136832","phase":"NA","title":"Pneumonia Vaccine Education Intervention Study","status":"COMPLETED","sponsor":"Geisinger Clinic","startDate":"2024-05-06","conditions":"Pneumonia, Pneumococcal, Vaccine","enrollment":141},{"nctId":"NCT07035054","phase":"PHASE2","title":"Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2024-04-20","conditions":"Streptococcus Pneumoniae Pneumonia","enrollment":992},{"nctId":"NCT07025876","phase":"EARLY_PHASE1","title":"PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2023-11-18","conditions":"Streptococcus Pneumoniae Pneumonia","enrollment":240},{"nctId":"NCT06970756","phase":"PHASE1","title":"A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60","status":"NOT_YET_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2025-05-27","conditions":"Pneumococcal Diseases","enrollment":60},{"nctId":"NCT05879107","phase":"PHASE3","title":"Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-05-26","conditions":"Respiratory Syncytial Virus Infections","enrollment":1113},{"nctId":"NCT06562790","phase":"PHASE1","title":"Study of Gamma PN3 in the Elderly","status":"COMPLETED","sponsor":"GPN Vaccines","startDate":"2024-08-26","conditions":"Pneumonia, Pneumococcal","enrollment":105},{"nctId":"NCT06474377","phase":"PHASE1","title":"Clinical Trial of PCV24 in Adults","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-06-21","conditions":"Pneumococcal Infectious Disease","enrollment":170},{"nctId":"NCT06731374","phase":"PHASE4","title":"Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2025-02-24","conditions":"Pneumococcal Disease, Pneumococcal Carriage","enrollment":106},{"nctId":"NCT06829238","phase":"PHASE4","title":"Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-07","conditions":"Systemic Inflammation, Immune Dysregulation, Injection Drug Use","enrollment":100},{"nctId":"NCT06056050","phase":"PHASE1","title":"A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2023-12-06","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":180},{"nctId":"NCT05691790","phase":"NA","title":"Older People's Preventive Care Utilization","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2024-10-01","conditions":"Health Communication","enrollment":270},{"nctId":"NCT06608199","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine","status":"RECRUITING","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2024-11-01","conditions":"Pneumococcal Vaccines, Pneumococcal Infections","enrollment":500},{"nctId":"NCT06708286","phase":"PHASE2, PHASE3","title":"A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-12-20","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1820},{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840},{"nctId":"NCT05827874","phase":"PHASE1","title":"A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-12","conditions":"Healthy","enrollment":32},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":"Chickenpox","enrollment":800},{"nctId":"NCT06817187","phase":"PHASE3","title":"Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-09-16","conditions":"Streptococcus Pneumoniae Infections","enrollment":1110},{"nctId":"NCT06813729","phase":"PHASE4","title":"Effects of Shotblocker® and Manual Pressure on Pain","status":"COMPLETED","sponsor":"Aydin Adnan Menderes University","startDate":"2022-02-15","conditions":"Healthy Volunteers, Infant, Vaccine","enrollment":102},{"nctId":"NCT06703203","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2024-08-27","conditions":"Pneumococcal Vaccines","enrollment":450},{"nctId":"NCT06693895","phase":"PHASE3","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-26","conditions":"Chickenpox","enrollment":750},{"nctId":"NCT01926860","phase":"PHASE4","title":"PCV13 + Hepatitis a Vaccine for Adults","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2013-08-24","conditions":"Measurement of Immune Response to Prevenar13, Measurement of Immune Response to Hepatitis a","enrollment":305},{"nctId":"NCT05175014","phase":"PHASE4","title":"Mass Campaigns With Fractional Dose Pneumococcal Vaccines in Sub-Saharan Africa (fPCV)","status":"COMPLETED","sponsor":"Epicentre","startDate":"2021-12-30","conditions":"Pneumococcal Carriage","enrollment":44618},{"nctId":"NCT05622942","phase":"PHASE1","title":"Clinical Trial of Recombinant Pneumococcal Protein Vaccine","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2023-03-11","conditions":"Pneumonia, Respiratory Tract Diseases, Respiratory Tract Infections","enrollment":60},{"nctId":"NCT03098628","phase":"PHASE2, PHASE3","title":"Trial of Simplified Pneumococcal Vaccination in Vietnam II","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2017-03-08","conditions":"Pneumococcal Vaccine","enrollment":2501},{"nctId":"NCT06678607","phase":"PHASE1","title":"Phase I Clinical Trial of PCV24 in People Aged 18 Years and Older","status":"COMPLETED","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2023-11-19","conditions":"Pneumococcal Infectious Disease","enrollment":240},{"nctId":"NCT05425732","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-13","conditions":"Pneumococcal Infection","enrollment":2663},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT05297578","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults","status":"COMPLETED","sponsor":"Vaxcyte, Inc.","startDate":"2022-06-15","conditions":"Pneumococcal Vaccines","enrollment":207},{"nctId":"NCT05633992","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-01-10","conditions":"Pneumococcal Disease","enrollment":450},{"nctId":"NCT05759520","phase":"PHASE3","title":"Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fosun Adgenvax Biopharmaceutical Co.,Ltd.","startDate":"2022-11-04","conditions":"Streptococcus Pneumoniae Infection","enrollment":1800},{"nctId":"NCT05464420","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-08-12","conditions":"Pneumococcal Disease","enrollment":2162},{"nctId":"NCT05667740","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.","status":"COMPLETED","sponsor":"GPN Vaccines","startDate":"2023-01-16","conditions":"Pneumococcal Infections","enrollment":118},{"nctId":"NCT04535037","phase":"PHASE4","title":"A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-26","conditions":"Diphtheria","enrollment":500},{"nctId":"NCT04275284","phase":"","title":"Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2020-02-14","conditions":"Pneumonia, Meningitis","enrollment":600},{"nctId":"NCT05831124","phase":"PHASE1","title":"A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-04-19","conditions":"Pneumococcal Disease","enrollment":90},{"nctId":"NCT03729778","phase":"EARLY_PHASE1","title":"Impact of HIV-1 and Aging on Mucosal Vaccine Responses","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Eastern Colorado Health Care System","startDate":"2017-01-18","conditions":"HIV-1-infection, Human Immunodeficiency Virus, HIV/AIDS","enrollment":100},{"nctId":"NCT05934890","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13","status":"ACTIVE_NOT_RECRUITING","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2023-11-23","conditions":"Pneumococcal Disease, Invasive","enrollment":630},{"nctId":"NCT05489328","phase":"PHASE1","title":"Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-15","conditions":"Pneumococcal Disease","enrollment":394},{"nctId":"NCT05266456","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults","status":"COMPLETED","sponsor":"Vaxcyte, Inc.","startDate":"2022-02-22","conditions":"Pneumococcal Vaccines","enrollment":835},{"nctId":"NCT06314867","phase":"PHASE3","title":"Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-01-30","conditions":"Healthy Volunteers","enrollment":990},{"nctId":"NCT04841369","phase":"PHASE3","title":"Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2021-04-13","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":3420},{"nctId":"NCT06337643","phase":"PHASE1","title":"A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Matrivax Research and Development Corporation","startDate":"2023-03-07","conditions":"Pneumococcal Vaccine","enrollment":75},{"nctId":"NCT03384589","phase":"PHASE2, PHASE3","title":"CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2018-08-23","conditions":"Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection","enrollment":248},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT04923035","phase":"","title":"Paediatric Pneumococcal Pneumonia in Malaysia Prior to and During Pneumococcal Conjugate Vaccine (PCV) Implementation","status":"UNKNOWN","sponsor":"IMU University, Malaysia","startDate":"2021-10-13","conditions":"Pneumonia, Pneumococcal, Pneumonia Childhood","enrollment":1010},{"nctId":"NCT04665050","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-04","conditions":"Pneumococcal Infection","enrollment":102},{"nctId":"NCT04515147","phase":"PHASE2","title":"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","status":"COMPLETED","sponsor":"CureVac","startDate":"2020-09-21","conditions":"Coronavirus, Covid19, SARS-CoV-2","enrollment":668},{"nctId":"NCT06044077","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People","status":"RECRUITING","sponsor":"Aimei Vacin BioPharm (Zhejiang) Co., Ltd.","startDate":"2023-09-08","conditions":"Pneumococcal Disease","enrollment":1920},{"nctId":"NCT05477693","phase":"PHASE4","title":"Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-10-25","conditions":"Pneumococcal Infections","enrollment":1800},{"nctId":"NCT05540028","phase":"PHASE1","title":"Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Inventprise Inc.","startDate":"2022-09-28","conditions":"Pneumococcal Vaccines","enrollment":65},{"nctId":"NCT03565900","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-12","conditions":"Pneumococcal Infections","enrollment":277}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1022,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"control pneumococcal polysaccharide vaccine","genericName":"control pneumococcal polysaccharide vaccine","companyName":"Aimei Vacin BioPharm (Zhejiang) Co., Ltd.","companyId":"aimei-vacin-biopharm-zhejiang-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine works by stimulating the body's immune system to produce antibodies against pneumococcal bacteria. Used for Prevention of pneumococcal disease in adults 18 years of age and older.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}